06/06/2018

A stem cell treatment which is in primary stages of trials, has proved effective in treatment when using non-donor stem cells.

Spinal cord injuries can happen to anyone, the condition tends to be a result of a fall or accident, although it can also be an outcome of a brain injury. When the spinal cord is injured the pathway is practically closed. Nerve impulses cant get through, this has problematic symptoms such as; a person suffering paralysis, a loss of mobility and sensation.

Using stem cell therapy where the stem cells havent been donated mean they are more likely to be accepted by the patient when they are injected.

This new trial was published on the 9th of May 2018 inScience Translational Medicine, a team of international scientist led by the University of California San Diego School of Medicine successfully grafted stem cells back into a spinal cord without aggravating the immune system or reducing it in any way.

The stem cells injected in the trial were accepted and survived long term without causing a tumor. Researchers also found that the same cells showed a long-term survival when injected into an injured spinal cord.

Senior author Martin Marsala, MD, professor in the Department of Anesthesiology at UC San Diego School of Medicine and a member of the Sanford Consortium for Regenerative Medicine, said: The promise of iPSCs is huge, but so too have been the challenges. In this study, weve demonstrated an alternate approach,

We took skin cells, then induced them to becomeneural precursor cells(NPCs), destined to become nerve cells. Because they are syngeneicgenetically identical with the cell-graftthey are immunologically compatible. They grow and differentiate with no immunosuppression required.

Co-author Samuel Pfaff, PhD, professor and Howard Hughes Medical Institute Investigator at Salk Institute for Biological Studies, said: Using RNA sequencing and innovative bioinformatic method to deconvolute the RNAs species-of-origin, the research team demonstrated that iPSC-derived neural precursors safely acquire the genetic characteristics of mature CNS tissue.

In their study, researchers found that the stem cells survived and differentiated into neurons and supporting glial cells. The grafted stem cells were detected to be working and responsive seven months after transplantation.

Researchers, then grafted stem cells into similar tissues in the body that had severespinal cord injuries, this injection of stem cells was then followed by a transient four-week course of drugs that suppress the immune system. The stem cells then could work in the spinal cord and begin to allow movement.

Our current experiments are focusing on generation and testing of clinical grade human iPSCs, which is the ultimate source of cells to be used in future clinical trials for treatment of spinal cord and central nervous system injuries in a syngeneic or allogeneic setting, said Marsala.

Because long-term post-grafting periodsone to two yearsare required to achieve a full graftedcells-induced treatment effect, the elimination of immunosuppressive treatment will substantially increase our chances in achieving more robust functional improvement in spinal trauma patients receiving iPSC-derived NPCs.

In our current clinical cell-replacement trials, immunosuppression is required to achieve the survival of allogeneic cell grafts. The elimination of immunosuppression requirement by using syngeneic cell grafts would represent a major step forward said co-author Joseph Ciacci, MD, a neurosurgeon at UC San Diego Health and professor of surgery at UC San Diego School of Medicine.

The treatment is expected to go to the next stage of trials in the next few years, with the hope that this stem cell therapy can be used in modern medicine.

This research forms another significant step towards stem cell therapy and spinal cord injury. Yet the type of cell used is still in contention when it comes to human application. iPSC are undoubtedlyauseful research tool in the laboratory and as a result because of their pluripotency, many scientists continue to hopethat they can one day be used for therapeutic applications, including regenerative medicine in humans. This strategy continues to proveproblematic ashave been shown to produce lesions and tumors when injected or transplanted.

This type of research does however contribute to ongoing developments for the use of stem cells, where possible use of Adult Stem Cells, known not to be problematic as a result of tumors could be used.

We believe the best stem cells to use in emergingtreatmentswill be the patients own stem cells as this doesnt require a search for a suitable donor and in turn, eliminates chances of the transplanted cells being rejected.

If you want more information on how you can protect your childs future health by banking their cells, get in touch with our friendly team today or order your free information pack.

See the rest here:
Stem Cell Therapy May Be The Cure For Spinal Cord Injury ...

Spinal Cord Stem Cells Comments Off on Stem Cell Therapy May Be The Cure For Spinal Cord Injury … | September 14th, 2019

JavaScript is disabled on your browser. Please enable JavaScript to use all the features on this page.Abstract

Stem cells have the potential to differentiate into cardiovascular cell lineages and to stimulate tissue regeneration in a paracrine/autocrine manner; thus, they have been extensively studied as candidate cell sources for cardiovascular regeneration. Several preclinical and clinical studies addressing the therapeutic potential of endothelial progenitor cells (EPCs) and cardiac progenitor cells (CPCs) in cardiovascular diseases have been performed. For instance, autologous EPC transplantation and EPC mobilization through pharmacological agents contributed to vascular repair and neovascularization in different animal models of limb ischemia and myocardial infarction. Also, CPC administration and in situ stimulation of resident CPCs have been shown to improve myocardial survival and function in experimental models of ischemic heart disease. However, clinical studies using EPC- and CPC-based therapeutic approaches have produced mixed results. In this regard, intracoronary, intra-myocardial or intramuscular injection of either bone marrow-derived or peripheral blood progenitor cells has improved pathological features of tissue ischemia in humans, despite modest or no clinical benefit has been observed in most cases. Also, the intriguing scientific background surrounding the potential clinical applications of EPC capture stenting is still waiting for a confirmatory proof. Moreover, clinical findings on the efficacy of CPC-based cell therapy in heart diseases are still very preliminary and based on small-size studies.

Despite promising evidence, widespread clinical application of both EPCs and CPCs remains delayed due to several unresolved issues. The present review provides a summary of the different applications of EPCs and CPCs for cardiovascular cell therapy and underlies their advantages and limitations.

bone marrow-derived cells

cardiac progenitor cells

C-X-C chemokine receptor type 4

1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine-acetylated low density lipoprotein

endothelial colony forming cells

endothelial progenitor cells

granulocyte colony-stimulating factor

individual patient data

induced pluripotent stem cells

platelet-derived growth factor receptor

stromal cell derived factor-1

stage specific embryonic antigen-1

ST-segment elevation myocardial infarction

vascular endothelial growth factor

Ulex europaeus agglutinin-1

Endothelial progenitor cells

Stem cells

EPC

CPC

Myocardial infarction

Regenerative medicine

Recommended articlesCiting articles (0)

2017 Elsevier Inc. All rights reserved.

Here is the original post:
Endothelial and cardiac progenitor cells for ...

Cardiac Stem Cells Comments Off on Endothelial and cardiac progenitor cells for … | June 6th, 2019

Cambridge Healthtech Institutes 4th AnnualJune 19-20, 2019

With advances in reprogramming and differentiation technologies, as well as with the recent availability of gene editing approaches, we are finally able to create more complex and phenotypically accurate cellular models based on pluripotent cell technology. This opens new and exciting opportunities for pluripotent stem cell utilization in early discovery, preclinical and translational research. CNS diseases and disorders are currently the main therapeutic area of application with some impressive success stories resulted in clinical trials. Cambridge Healthtech Institutes 4th Annual iPS Cells for Disease Modeling and Drug Discovery conference is designed to bring together experts and bench scientists working with pluripotent cells and end users of their services, researchers working on finding cures for specific diseases and disorders.

Day 1 | Day 2 | Download Brochure | Speaker Biographies

Wednesday, June 19

12:00 pm Registration Open

12:00 Bridging Luncheon Presentation:Structural Maturation in the Development of hiPSC-Cardiomyocyte Models for Pre-clinical Safety, Efficacy, and Discovery

Nicholas Geissse, PhD, CSO, NanoSurface Biomedical

Alec S.T. Smith, PhD, Acting Instructor, Bioengineering, University of Washington

hiPSC-CM maturation is sensitive to structural cues from the extracellular matrix (ECM). Failure to reproduce these signals in vitro can hamper experimental reproducibility and fidelity. Engineering approaches that address this gap typically trade off complexity with throughput, making them difficult to deploy in the modern drug development paradigm. The NanoSurface Car(ina) platform leverages ECM engineering approaches that are fully compatible with industry-standard instrumentation including HCI- and MEA-based assays, thereby improving their predictive power.

12:30 Transition to Plenary

12:50 PLENARY KEYNOTE SESSION

2:20Booth Crawl and Dessert Break in the Exhibit Hall with Poster Viewing

2:25 Meet the Plenary Keynotes

3:05 Chairpersons Remarks

Gabriele Proetzel, PhD, Director, Neuroscience Drug Discovery, Takeda Pharmaceuticals, Inc.

3:10 KEYNOTE PRESENTATION: iPSC-Based Drug Discovery Platform for Targeting Innate Immune Cell Responses

Christoph Patsch, PhD, Team Lead Stem Cell Assays, Disease Relevant Cell Models and Assays, Chemical Biology, Therapeutic Modalities, Roche Pharma Research and Early Development

The role of innate immune cells in health and disease, respectively their function in maintaining immune homeostasis and triggering inflammation makes them a prime target for therapeutic approaches. In order to explore novel therapeutic strategies to enhance immunoregulatory functions, we developed an iPSC-based cellular drug discovery platform. Here we will highlight the unique opportunities provided by an iPSC-based drug discovery platform for targeting innate immune cells.

3:40 Phenotypic Screening of Induced Pluripotent Stem Cell Derived Cardiomyocytes for Drug Discovery and Toxicity Screening

Arne Bruyneel, PhD, Postdoctoral Fellow, Mark Mercola Lab, Cardiovascular Institute, Stanford University School of Medicine

Cardiac arrhythmia and myopathy is a major problem with cancer therapeutics, including newer small molecule kinase inhibitors, and frequently causes heart failure, morbidity and death. However, currentin vitromodels are unable to predict cardiotoxicity, or are not scalable to aid drug development. However, with recent progress in human stem cell biology, cardiac differentiation protocols, and high throughput screening, new tools are available to overcome this barrier to progress.

4:10 Disease Modeling Using Human iPSC-Derived Telencephalic Inhibitory Interneurons - A Couple of Case Studies

Yishan Sun, PhD, Investigator, Novartis Institutes for BioMedical Research (NIBR)

Human iPSC-derived neurons provide the foundation for phenotypic assays assessing genetic or pharmacological effects in a human neurobiological context. The onus is on assay developers to generate application-relevant neuronal cell types from iPSCs, which is not always straightforward, given the diversity of neuronal classes in the human brain and their developmental trajectories. Here we present two case studies to illustrate the use of iPSC-derived telencephalic GABAergic interneurons in neuropsychiatric research.

4:40 Rethinking the Translational The Use of Highly Predictive hiPSC-Derived Models in Pre-Clinical Drug Development

Stefan Braam, CEO, Ncardia

Current drug development strategies are failing to increase the number of drugs reaching the market. One reason for low success rates is the lack of predictive models. Join our talk to learn how to implement a predictive and translational in vitro disease model, and assays for efficacy screening at any throughput.

5:10 4th of July Celebration in the Exhibit Hall with Poster Viewing

5:30 - 5:45 Speed Networking: Oncology

6:05 Close of Day

5:45 Dinner Short Course Registration

6:15 Dinner Short Course*

*Separate registration required.

Day 1 | Day 2 | Download Brochure | Speaker Biographies

Thursday, June 20

7:15 am Registration

7:15 Breakout Discussion Groups with Continental Breakfast

8:10 Chairpersons Remarks

Jeff Willy, PhD, Research Fellow, Discovery and Investigative Toxicology, Vertex

8:15 Levering iPSC to Understand Mechanism of Toxicity

Jeff Willy, PhD, Research Fellow, Discovery and Investigative Toxicology, Vertex

The discovery of mammalian cardiac progenitor cells suggests that the heart consists of not only terminally differentiated beating cardiomyocytes, but also a population of self-renewing stem cells. We recently showed that iPSC cardiomyocytes can be utilized not only to de-risk compounds with potential for adverse cardiac events, but also to understand underlying mechanisms of cell-specific toxicities following xenobiotic stress, thus preventing differentiation and self-renewal of damaged cells.

8:45Pluripotent Stem Cell-Derived Cardiac and Vascular Progenitor Cells for Tissue Regeneration

Nutan Prasain, PhD, Associate Director, Cardiovascular Programs, Astellas Institute for Regenerative Medicine (AIRM)

This presentation will provide the review on recent discoveries in the derivation and characterization of cardiac and vascular progenitor cells from pluripotent stem cells, and discuss the therapeutic potential of these cells in cardiac and vascular tissue repair and regeneration.

9:15 Use of iPSCDerived Hepatocytes to Identify Treatments for Liver Disease

Stephen A. Duncan, PhD, Smartstate Chair in Regenerative Medicine, Professor and Chairman, Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina

MTDPS3 is a rare disease caused by mutations in the DGUOK gene, which is needed for mitochondrial DNA (mtDNA) replication and repair. Patients commonly die as children from liver failure primarily caused by unmet energy requirements. We modeled the disease using DGOUK deficient iPSC derived hepatocytes and performed a screen to identify drugs that can restore mitochondrial ATP production.

9:45Industrial-Scale Generation of Human iPSC-Derived Hepatocytes for Liver-Disease and Drug Development Studies

Liz Quinn, PhD, Associate Director, Stem Cell Marketing, Marketing, Takara Bio USA

Our optimized hepatocyte differentiation protocol and standardized workflow mimics embryonic development and allows for highly efficient differentiation of hPSCs through definitive endoderm into hepatocytes. We will describe the creation of large panels of industrial-scale hPSC-derived hepatocytes with specific genotypes and phenotypes and their utility for drug metabolism and disease modeling.

10:00 Sponsored Presentation (Opportunity Available)

10:15 Coffee Break in the Exhibit Hall with Poster Viewing

10:45 Poster Winner Announced

11:00 KEYNOTE PRESENTATION: Modeling Human Disease Using Pluripotent Stem Cells

Lorenz Studer, MD, Director, Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center

One of the most intriguing applications of human pluripotent stem cells is the possibility of recreating a disease in a dish and to use such cell-based models for drug discovery. Our lab uses human iPS and ES cells for modeling both neurodevelopmental and neurodegenerative disorders. I will present new data on our efforts of modeling complex genetic disease using pluripotent stem cells and the development of multiplex culture systems.

11:30 Preclinical Challenges for Gene Therapy Approaches in Neuroscience

Gabriele Proetzel, PhD, Director, Neuroscience Drug Discovery, Takeda Pharmaceuticals, Inc.

Gene therapy has delivered encouraging results in the clinic, and with the first FDA approval for an AAV product is now becoming a reality. This presentation will provide an overview of the most recent advances of gene therapy for the treatment of neurological diseases. The discussion will focus on preclinical considerations for gene therapy including delivery, efficacy, biodistribution, animal models and safety.

12:00 pm Open Science Meets Stem Cells: A New Drug Discovery Approach for Neurodegenerative Disorders

Thomas Durcan, PhD, Assistant Professor, Neurology and Neurosurgery, McGill University

Advances in stem cell technology have provided researchers with tools to generate human neurons and develop first-of-their-kind disease-relevant assays. However, it is imperative that we accelerate discoveries from the bench to the clinic and the Montreal Neurological Institute (MNI) and its partners are piloting an Open Science model. By removing the obstacles in distributing patient samples and assay results, our goal is to accelerate translational medical research.

12:30 Elevating Drug Discovery with Advanced Physiologically Relevant Human iPSC-Based Screening Platforms

Fabian Zanella, PhD, Director, Research and Development, StemoniX

Structurally engineered human induced pluripotent stem cell (hiPSC)-based platforms enable greater physiological relevance, elevating performance in toxicity and discovery studies. StemoniXs hiPSC-derived platforms comprise neural (microBrain) or cardiac (microHeart) cells constructed with appropriate inter- and intracellular organization promoting robust activity and expected responses to known cellular modulators.

1:00Overcoming Challenges in CNS Drug Discovery through Developing Translatable iPSC-derived Cell-Based Assays

Jonathan Davila, PhD, CEO, Co-Founder, NeuCyte Inc.

Using direct reprogramming of iPSCs to generate defined human neural tissue, NeuCyte developed cell-based assays with complex neuronal structure and function readouts for versatile pre-clinical applications. Focusing on electrophysiological measurements, we demonstrate the capability of this approach to identify adverse neuroactive effects, evaluate compound efficacy, and serve phenotypic drug discovery.

1:15Enjoy Lunch on Your Own

1:35 Dessert and Coffee Break in the Exhibit Hall with Poster Viewing

1:45 - 2:00 Speed Networking: Last Chance to Meet with Potential Partners and Collaborators!

2:20 Chairpersons Remarks

Gary Gintant, PhD, Senior Research Fellow, AbbVie

2:25 The Evolving Roles of Evolving Human Stem Cell-Derived Cardiomyocyte Preparations in Cardiac Safety Evaluations

Gary Gintant, PhD, Senior Research Fellow, AbbVie

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) hold great promise for preclinical cardiac safety testing. Recent applications focus on drug effects on cardiac electrophysiology, contractility, and structural toxicities, with further complexity provided by the growing number of hiPSC-CM preparations being developed that may also promote myocyte maturity. The evolving roles (both non-regulatory and regulatory) of these preparations will be reviewed, along with general considerations for their use in cardiac safety evaluations.

2:55 Pharmacogenomic Prediction of Drug-Induced Cardiotoxicity Using hiPSC-Derived Cardiomyocytes

Paul W. Burridge, PhD, Assistant Professor, Department of Pharmacology, Center for Pharmacogenomics, Northwestern University Feinberg School of Medicine

We have demonstrated that human induced pluripotent stem cell-derived cardiomyocytes successfully recapitulate a patients predisposition to chemotherapy-induced cardiotoxicity, confirming that there is a genomic basis for this phenomenon. Here we will discuss our recent work deciphering the pharmacogenomics behind this relationship, allowing the genomic prediction of which patients are likely to experience this side effect. Our efforts to discover new drugs to prevent doxorubicin-induced cardiotoxicity will also be reviewed.

3:25 Exploring the Utility of iPSC-Derived 3D Cortical Spheroids in the Detection of CNS Toxicity

Qin Wang, PhD, Scientist, Drug Safety Research and Evaluation, Takeda

Drug-induced Central Nervous System (CNS) toxicity is a common safety attrition for project failure during discovery and development phases due low concordance rates between animal models and human, absence of clear biomarkers, and a lack of predictive assays. To address the challenge, we validated a high throughput human iPSC-derived 3D microBrain model with a diverse set of pharmaceuticals. We measured drug-induced changes in neuronal viability and Ca channel function. MicroBrain exposure and analyses were rooted in therapeutic exposure to predict clinical drug-induced seizures and/or neurodegeneration. We found that this high throughput model has very low false positive rate in the prediction of drug-induced neurotoxicity.

3:55 Linking Liver-on-a-Chip and Blood-Brain-Barrier-on-a-Chip for Toxicity Assessment

Sophie Lelievre, DVM, PhD, LLM, Professor, Cancer Pharmacology, Purdue University College of Veterinary Medicine

One of the challenges to reproduce the function of tissues in vitro is the maintenance of differentiation. Essential aspects necessary for such endeavor involve good mechanical and chemical mimicry of the microenvironment. I will present examples of the management of the cellular microenvironment for liver and blood-brain-barrier tissue chips and discuss how on-a-chip devices may be linked for the integrated study of the toxicity of drugs and other molecules.

4:25 Close of Conference

Day 1 | Day 2 | Download Brochure | Speaker Biographies

Arrive early to attend Tuesday, June 18 - Wednesday, June 19

Chemical Biology and Target Validation

Continue reading here:
iPS Cells for Disease Modeling and Drug Discovery

IPS Cell Therapy Comments Off on iPS Cells for Disease Modeling and Drug Discovery | June 4th, 2019

Open AccessReview

1

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal

2

ICVS/3BsPT Government Associate Laboratory, Braga/Guimares, Portugal

*

Author to whom correspondence should be addressed.

Received: 12 March 2019 / Revised: 15 April 2019 / Accepted: 23 April 2019 / Published: 29 April 2019

No

MDPI and ACS Style

Pereira, I.M.; Marote, A.; Salgado, A.J.; Silva, N.A. Filling the Gap: Neural Stem Cells as A Promising Therapy for Spinal Cord Injury. Pharmaceuticals 2019, 12, 65.

Pereira IM, Marote A, Salgado AJ, Silva NA. Filling the Gap: Neural Stem Cells as A Promising Therapy for Spinal Cord Injury. Pharmaceuticals. 2019; 12(2):65.

Pereira, Ins M.; Marote, Ana; Salgado, Antnio J.; Silva, Nuno A. 2019. "Filling the Gap: Neural Stem Cells as A Promising Therapy for Spinal Cord Injury." Pharmaceuticals 12, no. 2: 65.

Show more citation formatsShow less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

No

No

Link:
Filling the Gap: Neural Stem Cells as A Promising Therapy ...

Spinal Cord Stem Cells Comments Off on Filling the Gap: Neural Stem Cells as A Promising Therapy … | June 3rd, 2019

Overview of current stem cell-based approaches to treat heart disease

Since heart failure after heart attacks results from death of heart muscle cells, researchers have been developing strategies to remuscularize the damaged heart wall in efforts to improve its function. Researchers are transplanting different types of stem cell and progenitor cells (see above) into patients to repair the damaged heart muscle. These strategies have mainly used either adult stem cells (found in bone marrow, fat, or the heart itself) or pluripotent (ES or iPS) cells.

Preliminary results from experiments with adult stem cells showed that they appeared to improve cardiac function even though they died shortly after transplantation. This led to the idea that these cells can release signals that can improve function without replacing the lost muscle. Clinical trials began in the early 2000s transplanting adult stem cells from the bone marrow and then from the heart. These trials demonstrated that transplanting cells into damaged hearts is feasible and generally safe for patients. However, larger trials that were randomized, blinded, and placebo-controlled, showed fewer indications of improved function. The consensus now is that adult stem cells have modest, if any, benefit to cardiac function.

Research shows that pluripotent stem cell-derived cardiomyocytes can form beating human heart muscle cells that both release the necessary signals and replace muscle lost to heart attack. Transplantation of pluripotent stem cell-derived cardiac cells have demonstrated substantial benefits to cardiac function in animal models of heart disease, from mice to monkeys. Recently, pluripotent stem cell-derived interventions were used in clinical trials for the first time. Patches of human heart muscle cells derived from the stem cells were transplanted onto the surface of failing hearts. Early results suggest that this approach is feasible and safe, but it is too early to know whether there are functional benefits.Research is ongoing to test cellular therapies to treat heart attacks by combining different types of stem cells, repeating transplantations, or improving stem cell patches. Clinical trials using these improved methods are currently targeted to begin around 2020.Unfortunately, many unscrupulous clinics are making unsubstantiated claims about the efficacy of stem cell therapies for heart failure, creating confusion about the current state of cellular approaches for heart failure. To learn more about warning signs of these unproven interventions, please visit Nine Things to Know About Stem Cell Treatments.

See the original post here:
Heart Disease A Closer Look at Stem Cells

Cardiac Stem Cells Comments Off on Heart Disease A Closer Look at Stem Cells | June 1st, 2019

Stem cells can do a lot of things - they can heal damaged tissue, reduce inflammation and restore function to damaged tissues. Did you know that stem cells can also improve your skin's quality and reduce the signs of aging? Innovations Stem Cell Center offers fat stem cell therapy for not only a wide array of medical conditions, but also for powerful anti-aging benefits.

How Can Stem Cell Therapy Improve Skin Quality?

Stem cells can help improve skin quality by helping to heal tissues that have been damaged by:

Aging. The aging process causes the breakdown of skin cells and skin quality, leaving the skin looking dull and dirty. Skin also loses elasticity and tightness.

Genetics. Genetics plays a large part in how your skin ages, and it's hard to fight it with over-the-counter products and treatments.

Poor diet. Lack of quality nutrition can negatively impact both the body and the skin. When the skin is not supported through a healthy diet, skin becomes dull, drab and damaged.

Environment. Environmental factors that affect the skin include pollution, dirt and germs. These things clog the pores, dull your appearance and lead to blemishes, acne and breakouts. Environmental factors also include prolonged exposure to the sun, which can cause pigmentation problems and destroy collagen and elastin.

How Is Stem Cell Therapy Used for the Skin?

One of the ways stem cell therapy is used for the skin is through a stem cell face-lift procedure. During this treatment, Dr. Johnson harvests stem cells from unwanted fat taken from another area of your body, such as your lower back or abdomen.

After the cells are harvested, they are separated from the blood and other tissue and then injected into your face with tiny needles.

The stem cell face-lift can be combined with other procedures, such as the facial fat transfer. Combining the procedures increases the odds of stem cell survival and boosts the anti-aging benefits.

What Are the Benefits of Stem Cell Therapy for the Skin?

Patients who undergo stem cell therapy for anti-aging benefits see changes in their skin such as:

Are you interested in learning more about stem cell therapy and its benefits for your skin? Call Innovations Stem Cell today at 214-256-1462 to learn more.

Go here to read the rest:
Stem Cells for Skin Quality - innovationsstemcellcenter.com

Skin Stem Cells Comments Off on Stem Cells for Skin Quality – innovationsstemcellcenter.com | May 27th, 2019

JavaScript is disabled on your browser. Please enable JavaScript to use all the features on this page.Highlights

NSI-566 grafted injured spines in rats with near complete cavity-filling

The differentiation profile of grafted cells showed all three neural lineage cells

High-density human axonal sprouting was seen throughout the NSI-566 grafted region

NSI-566 transplanted in the spinal injury site of patients can be performed safely

We tested the feasibility and safety of human-spinal-cord-derived neural stem cell (NSI-566) transplantation for the treatment of chronic spinal cord injury (SCI). In this clinical trial, four subjects with T2T12 SCI received treatment consisting of removal of spinal instrumentation, laminectomy, and durotomy, followed by six midline bilateral stereotactic injections of NSI-566 cells. All subjects tolerated the procedure well and there have been no serious adverse events to date (1827months post-grafting). In two subjects, one to two levels of neurological improvement were detected using ISNCSCI motor and sensory scores. Our results support the safety of NSI-566 transplantation into the SCI site and earlysigns of potential efficacy in three of the subjects warrant further exploration of NSI-566 cells in dose escalation studies. Despite these encouraging secondary data, we emphasize that this safety trial lacks statistical power or a control group needed to evaluate functional changes resulting from cell grafting.

spinal cord injury

SCI

stem cell therapy

spinal surgery

Recommended articlesCiting articles (0)

2018 Elsevier Inc.

Read this article:
A First-in-Human, Phase I Study of Neural Stem Cell ...

Spinal Cord Stem Cells Comments Off on A First-in-Human, Phase I Study of Neural Stem Cell … | May 26th, 2019

'); jQuery('.cart-remove-box a').on('click', function(){ link = jQuery(this).attr('href'); jQuery.ajax({ url: link, cache: false }); jQuery('.cart-remove-box').remove(); setTimeout(function(){window.location.reload();}, 800); }); }); //jQuery('#ajax_loader').hide(); // clear being added addToCartButton.text(defaultText).removeAttr('disabled').removeClass('disabled'); addToCartButton.parent().find('.disabled-blocker').remove(); loadingDots.remove(); clearInterval(loadingDotId); jQuery('body').append(""); setTimeout(function () {jQuery('.add-to-cart-success').slideUp(500)}, 5000); }); } try { jQuery.ajax( { url : url, dataType : 'json', type : 'post', data : data, complete: function(){ if(jQuery('body').hasClass('product-edit') || jQuery('body').hasClass('wishlist-index-configure')){ jQuery.ajax({ url: "https://www.stemcell.com/meigeeactions/updatecart/", cache: false }).done(function(html){ jQuery('header#header .top-cart').replaceWith(html); }); jQuery('#ajax_loader').hide(); jQuery('body').append(""); setTimeout(function () {jQuery('.add-to-cart-success').slideUp(500)}, 5000); } }, success : function(data) { if(data.status == 'ERROR'){ jQuery('body').append(''); }else{ ajaxComplete(); } } }); } catch (e) { } // End of our new ajax code this.form.action = oldUrl; if (e) { throw e; } } }.bind(productAddToCartForm); productAddToCartForm.submitLight = function(button, url){ if(this.validator) { var nv = Validation.methods; delete Validation.methods['required-entry']; delete Validation.methods['validate-one-required']; delete Validation.methods['validate-one-required-by-name']; if (this.validator.validate()) { if (url) { this.form.action = url; } this.form.submit(); } Object.extend(Validation.methods, nv); } }.bind(productAddToCartForm); function setAjaxData(data,iframe,name,image){ if(data.status == 'ERROR'){ jQuery('body').append(''); }else{ if(data.sidebar && !iframe){ if(jQuery('.top-cart').length){ jQuery('.top-cart').replaceWith(data.sidebar); } if(jQuery('.sidebar .block.block-cart').length){ if(jQuery('#cart-sidebar').length){ jQuery('#cart-sidebar').html(jQuery(data.sidebar).find('#mini-cart')); jQuery('.sidebar .block.block-cart .subtotal').html(jQuery(data.sidebar).find('.subtotal')); }else{ jQuery('.sidebar .block.block-cart p.empty').remove(); content = jQuery('.sidebar .block.block-cart .block-content'); jQuery('').appendTo(content); jQuery('').appendTo(content); content.find('#cart-sidebar').html(jQuery(data.sidebar).find('#mini-cart').html()); content.find('.actions').append(jQuery(data.sidebar).find('.subtotal')); content.find('.actions').append(jQuery(data.sidebar).find('.actions button.button')); } cartProductRemove('#cart-sidebar li.item a.btn-remove', { confirm: 'Are you sure you would like to remove this item from the shopping cart?', submit: 'Ok', calcel: 'Cancel' }); } jQuery.fancybox.close(); jQuery('body').append(''); }else{ jQuery.ajax({ url: "https://www.stemcell.com/meigeeactions/updatecart/", cache: false }).done(function(html){ jQuery('header#header .top-cart').replaceWith(html); jQuery('.top-cart #mini-cart li.item a.btn-remove').on('click', function(event){ event.preventDefault(); jQuery('body').append('Are you sure you would like to remove this item from the shopping cart?OkCancel'); jQuery('.cart-remove-box a').on('click', function(){ link = jQuery(this).attr('href'); jQuery.ajax({ url: link, cache: false }); jQuery('.cart-remove-box').remove(); setTimeout(function(){window.location.reload();}, 800); }); }); jQuery.fancybox.close(); jQuery('body').append(''); }); } } setTimeout(function () {jQuery('.add-to-cart-success').slideUp(500)}, 5000); } //]]> CloneR is a defined, serum-free supplement designed to increase the cloning efficiency and single-cell survival of human embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells). CloneR enables the robust generation of clonal cell lines without single-cell adaptation, thus minimizing the risk of acquiring genetic abnormalities.

CloneR is compatible with the TeSR family of media for human ES and iPS cell maintenance as well as your choice of cell culture matrix.

Advantages:

Greatly facilitates the process of genome editing of human ES and iPS cells Compatible with any TeSR maintenance medium and your choice of cell culture matrix Does not require adaptation to single-cell passaging Increases single-cell survival at clonal density across multiple human ES and iPS cell lines

Cell Type:

Pluripotent Stem Cells

Application:

Cell Culture

Area of Interest:

Cell Line Development; Stem Cell Biology; Disease Modeling

Formulation:

Defined; Serum-Free

Document Type

Product Name

Catalog #

Lot #

Language

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Research Area Workflow Stages for

Workflow Stages

Figure 1. hPSC Single-Cell Cloning Workflow with CloneR

On day 0, human pluripotent stem cells (hPSCs) are seeded as single cells at clonal density (e.g. 25 cells/cm2) or sorted at 1 cell per well in 96-well plates in TeSR (mTeSR1 or TeSR-E8) medium supplemented with CloneR. On day 2, the cells are fed with TeSR medium containing CloneR supplement. From day 4, cells are maintained in TeSR medium without CloneR. Colonies are ready to be picked between days 10 - 14. Clonal cell lines can be maintained long-term in TeSR medium.

Figure 2. CloneR Increases the Cloning Efficiency of hPSCs and is Compatible with Multiple hPSC Lines and Seeding Protocols

TeSR medium supplemented with CloneR increases hPSC cloning efficiency compared with cells plated in TeSR containing ROCK inhibitor. Cells were seeded (A) at clonal density (25 cells/cm2) in mTeSR1 and TeSR-E8 and (B) by single-cell deposition using FACS (seeded at 1 cell/well) in mTeSR1.

Figure 3. CloneR Increases the Cloning Efficiency of hPSCs at Low Seeding Densities

hPSCs plated in mTeSR1 supplemented with CloneR demonstrated significantly increased cloning efficiencies compared to cells plated in mTeSR1 containing ROCK inhibitor (10M Y-27632). Shown are representative images of alkaline phosphatase-stained colonies at day 7 in individual wells of a 12-well plate. H1 human embryonic stem (hES) cells were seeded at clonal density (100 cells/well, 25 cells/cm2) in mTeSR1 supplemented with (A) ROCK inhibitor or (B) CloneR on Vitronectin XF cell culture matrix.

Figure 4. CloneR Yields Larger Single-Cell Derived Colonies

hPSCs seeded in mTeSR1 supplemented with CloneR result in larger colonies than cells seeded in mTeSR1 containing ROCK inhibitor (10M Y-27632). Shown are representative images of hPSC clones established after 7 days of culture in mTeSR1 supplemented with (A) ROCK inhibitor or (B) CloneR.

Figure 5. Clonal Cell Lines Established Using CloneR Display Characteristic hPSC Morphology

Clonal cell lines established using mTeSR1 or TeSR-E8 medium supplemented with CloneR retain the prominent nucleoli and high nuclear-to-cytoplasmic ratio characteristic of hPSCs. Representative images at passage 7 after cloning are shown for clones derived from the parental (A) H1 hES cell and (B) WLS-1C human induced pluripotent stem (iPS) cell lines.

Figure 6. Clonal Cell Lines Established with CloneR Express High Levels of Undifferentiated Cell Markers

hPSC clonal cell lines established using mTeSR1 supplemented with CloneR express comparable levels of undifferentiated cell markers, OCT4 (Catalog #60093) and TRA-1-60 (Catalog #60064), as the parental cell lines. (A) Clonal cell lines established from parental H1 hES cell line. (B) Clonal cell lines established from parental WLS-1C hiPS cell line. Data is presented between passages 5 - 7 after cloning and is shown as mean SEM; n = 2.

Figure 7. Clonal Cell Lines Established Using CloneR Display a Normal Karyotype

Representative karyograms of clones derived from parental (A) H1 hES cell and (B) WLS-1C hiPS cell lines demonstrate that the clonal lines established with CloneR have a normal karyotype. Cells were karyotyped 5 passages after cloning, with an overall passage number of 45 and 39, respectively.

Figure 8. Clonal Cell Lines Established Using CloneR Display Normal Growth Rates

Fold expansion of clonal cell lines display similar growth rates to parental cell lines. Shown are clones (red) and parental cell lines (gray) for (A) H1 hES cell and (B) WLS-1C hiPS cell lines.

STEMCELL TECHNOLOGIES INC.S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Internal Search Keywords: genome editing | cloning | CRISPR | clone | gene editing | 05888 | 5888 | single cell | accutase

Read more:
CloneR hPSC Cloning Supplement - Stemcell Technologies

IPS Cell Therapy Comments Off on CloneR hPSC Cloning Supplement – Stemcell Technologies | May 25th, 2019

JavaScript is disabled on your browser. Please enable JavaScript to use all the features on this page.Abstract

Bone has well documented natural healing capacity that normally is sufficient to repair fractures and other common injuries. However, the properties of bone change throughout life, and aging is accompanied by increased incidence of bone diseases and compromised fracture healing capacity, which necessitate effective therapies capable of enhancing bone regeneration. The therapeutic potential of adult mesenchymal stem cells (MSCs) for bone repair has been long proposed and examined. Actions of MSCs may include direct differentiation to become bone cells, attraction and recruitment of other cells, or creation of a regenerative environment via production of trophic growth factors. With systemic aging, MSCs also undergo functional decline, which has been well investigated in a number of recent studies. In this review, we first describe the changes in MSCs during aging and discuss how these alterations can affect bone regeneration. We next review current research findings on bone tissue engineering, which is considered a promising and viable therapeutic solution for structural and functional restoration of bone. In particular, the importance of MSCs and bioscaffolds is highlighted. Finally, potential approaches for the prevention of MSC aging and the rejuvenation of aged MSC are discussed.

MSC

Aging

Stem cell niche

Bone healing

Rejuvenation

Recommended articlesCiting articles (0)

2018 Published by Elsevier Ltd.

Read more from the original source:
Bone marrow mesenchymal stem cells: Aging and tissue ...

Bone Marrow Stem Cells Comments Off on Bone marrow mesenchymal stem cells: Aging and tissue … | May 23rd, 2019

Did you know that around 10,000 skin cells are born from one stem cell? Skin cells are constantly regenerating and on average live for 21 days. They make their way up from the deepest layers of your skin where they then die protecting themselves from external aggressors. As the engine for the constant renewal of your skin it is important we nourish and protect precious stem cells so they can keep producing your best skin.

As you age the activity of stem cells decrease. This is when you start to notice those first signs of ageing; thinner and more delicate skin, sagging, wrinkles and lack of luminosity. After the age of 40, the skins regeneration cycle slows down. New skin cells take longer to reach the surface of the skin, and dead cells can take twice as long to disappear, affecting the youthful appearance of your skin.

Do skincare products and skin treatments with stem cells make sense before the age of 40?Yes!

Young skin regenerates more quickly, and to mimic this we suggest an aggressive treatment, such as a peel, which removes lots of dead skin cells at once, to thenhelp your stem cells to renew andactivate the production of new, healthy and strong skin cells more quickly. Then we recommend stem cell skin products and treatments.

How exactly does a stem cell treatment work? The answer seems simple, but it is the result of many years of scientific research to ensure proven results. At Skeyndor we can guarantee this thanks to our laboratories with more than 50 years of experience in cosmeceuticals. Thanks to our incredible scientists, who have been at the forefront of skin stem cell innovations and breakthroughs we have developed two lines that contain stem cells.

Eternal:Skeyndors Eternalrangecontains the regenerative power of liposomes, derived from apple origin stem cells.These act on your skin stem cells to produce a greater amount of vital dermal substances, filling wrinkles, firming the skin and bringing luminosity to the face.

Timeless Prodigy: Timeless Prodigy by Skeyndor is a technological jewel to globally and definitively fight against the signs of skin ageing. Its formulation contains the revitalizing power of 50 million Damascus rose stem cells and is combined with the power of 10 other active ingredients, including five growth factors, white truffle and kombucha to eliminate signs of ageing. Including wrinkles and sagging, hydrating the skin in depth to revitalize its appearance and create that youthful glow. Timeless Prodigy is exclusive to select Skeyndor Spas and Beauty Salons.

Find your closest Eternal and Timeless Prodigy stockists to see the results for yourself, click here.

Related

See more here:
What Can Stem Cells Do For Your Skin? | Skeyndor Australia

Skin Stem Cells Comments Off on What Can Stem Cells Do For Your Skin? | Skeyndor Australia | May 21st, 2019

About stem cells

Stem cells are the foundation of development in plants, animals and humans. In humans, there are many different types of stem cells that come from different places in the body or are formed at different times in our lives. These include embryonic stem cells that exist only at the earliest stages of development and various types oftissue-specific(oradult)stem cells that appear during fetal development and remain in our bodies throughout life.Stem cells are defined by two characteristics:

Beyond these two things, though, stem cells differ a great deal in their behaviors and capabilities.

Embryonic stem cells arepluripotent, meaning they can generate all of the bodys cell types but cannot generate support structures like the placenta and umbilical cord.

Other cells aremultipotent,meaning they can generate a few different cell types, generally in a specific tissue or organ.

As the body develops and ages, the number and type of stem cells changes. Totipotent cells are no longer present after dividing into the cells that generate the placenta and umbilical cord. Pluripotent cells give rise to the specialized cells that make up the bodys organs and tissues. The stem cells that stay in your body throughout your life are tissue-specific, and there is evidence that these cells change as you age, too your skin stem cells at age 20 wont be exactly the same as your skin stem cells at age 80.

Learn more about different types of stem cellshere.

Read the rest here:
Stem Cell Basics A Closer Look at Stem Cells

Skin Stem Cells Comments Off on Stem Cell Basics A Closer Look at Stem Cells | May 21st, 2019

"Stem Cell Cure Pvt. Ltd." is one of the most trusted and highlighted company in India which has expertise in providing best Stem Cell Services (for Blood disorders) in top most hospital of India for all major degenerative diseases. Our company is providing advanced medical treatment in India which applies in case of all other medical treatment fail to cure non-treatable diseases. We provide our services through some medical devices such as bone marrow aspiration concentrate (BMAC) kit, platelet rich plasma (PRP) kit, stem cell banking and stem cells services (isolated from bone marrow, placenta and adipose) for research/clinical trial purpose only.We are providing advanced medical treatment in India where all other medical treatment fail then this stem cell treatment apply to cure such non-treatable diseases.

It is the single channel that has comprehensive stem cell treatment and other medical treatment protocols and employs stem cells in different form as per the requirement of best suite on the basis of degenerative disease application. Stem cell therapy is helpful to treat many blood disorder such as thalassemia, sickle cell anemia, leukemia, aplastic anemia and other organ related disorder such as muscular dystrophy, spinal cord Injury, diabetes, chronic kidney disease (CKD), cerebral palsy, autism, optic nerve atrophy, retinitis pigmentosa, lung (COPD) disease and liver cirrhosis and our list of services doesn't end here.

"Stem Cell Cure" company is working with some India's top stem cell therapy centers, cord blood stem cell preservation banks and approved stem cell research labs to explore and share their unique stem cell solutions with our best services via coordinating of our clinician and researcher and solving every type of patient queries regarding stem cell therapy.

Our company is providing best medical treatment in India and also has expertization in stem cell therapy and for the needed patients in all those application which can treat by stem cell therapy. We have stem cells in different forms to make the better recovery of patient and refer the best stem cell solutions after the evaluation of patient case study by our experts. Our experts in this field work together with patients though the collaborative patient experience to give you greater peace of mind to develop clear evidence based path. We have highly experts in our team and our experts are strong in research and clinical research from both points of view.

Our mission is to provide best stem cell therapy at reasonable price not only in India but also throughout the whole world so that every needed patients can get best stem cell therapy to improve his life.

The rest is here:
Stem Cell Therapy in India - Stem Cell Treatment in Delhi ...

Spinal Cord Stem Cells Comments Off on Stem Cell Therapy in India – Stem Cell Treatment in Delhi … | May 20th, 2019

JavaScript is disabled on your browser. Please enable JavaScript to use all the features on this page.Abstract

Oxidative stress on transplanted bone marrow-derived mesenchymal stem cells (BMSCs) during acute inflammation is a critical issue in cell therapies. N-acetyl-L cysteine (NAC) promotes the production of a cellular antioxidant molecule, glutathione (GSH). The aim of this study was to investigate the effects of pre-treatment with NAC on the apoptosis resistance and bone regeneration capability of BMSCs. Rat femur-derived BMSCs were treated in growth medium with or without 5mM NAC for 6h, followed by exposure to 100MH2O2 for 24h to induce oxidative stress. Pre-treatment with NAC significantly increased intracellular GSH levels by up to two fold and prevented H2O2-induced intracellular redox imbalance, apoptosis and senescence. When critical-sized rat femur defects were filled with a collagen sponge containing fluorescent-labeled autologous BMSCs with or without NAC treatment, the number of apoptotic and surviving cells in the transplanted site after 3 days was significantly lower and higher in the NAC pre-treated group, respectively. By the 5th week, significantly enhanced new bone formation was observed in the NAC pre-treated group. These data suggest that pre-treatment of BMSCs with NAC before local transplantation enhances bone regeneration via reinforced resistance to oxidative stress-induced apoptosis at the transplanted site.

Acute inflammation

Apoptosis

Cell conditioning

Glutathione

Local transplantation

Senescence

Recommended articlesCiting articles (0)

2018 Elsevier Ltd. All rights reserved.

Originally posted here:
Preconditioning of bone marrow-derived mesenchymal stem ...

Bone Marrow Stem Cells Comments Off on Preconditioning of bone marrow-derived mesenchymal stem … | May 20th, 2019

JavaScript is disabled on your browser. Please enable JavaScript to use all the features on this page.Highlights

Human iPS cell-derived neural progenitors influence the contractile property of cardiac spheroid.

The contractile function of spheroids depends on the ratio of neural progenitors to cardiac cells.

Neural factors may influence the contractile function of the spheroids.

We havebeen attempting to use cardiac spheroids to construct three-dimensional contractilestructures for failed hearts. Recent studies have reported that neuralprogenitors (NPs) play significant roles in heart regeneration. However, theeffect of NPs on the cardiac spheroid has not yet been elucidated.

This studyaims to demonstrate the influence of NPs on the function of cardiac spheroids.

Thespheroids were constructed on a low-attachment-well plate by mixing humaninduced pluripotent stem (hiPS) cell-derived cardiomyocytes and hiPScell-derived NPs (hiPS-NPs). The ratio of hiPS-NPs was set at 0%, 10%, 20%,30%, and 40% of the total cell number of spheroids, which was 2500. The motionwas recorded, and the fractional shortening and the contraction velocity weremeasured.

Spheroidswere formed within 48 h after mixing the cells, except for the spheroidscontaining 0% hiPS-NPs. Observation at day 7 revealed significant differencesin the fractional shortening (analysis of variance; p=0.01). The bestfractional shortening was observed with the spheroids containing 30% hiPS-NPs.Neuronal cells were detected morphologically within the spheroids under aconfocal microscope.

Theaddition of hiPS-NPs influenced the contractile function of the cardiacspheroids. Further studies are warranted to elucidate the underlying mechanism.

Human iPS cell

Cardiomyocyte

Neural progenitor

Spheroid

Recommended articlesCiting articles (0)

2018 Elsevier Ltd. All rights reserved.

Read the original:
The addition of human iPS cell-derived neural progenitors ...

IPS Cell Therapy Comments Off on The addition of human iPS cell-derived neural progenitors … | May 20th, 2019

One of the current challenges for stem cell researchers is to understand how all the skin appendages are regenerated. This could lead to improved treatments for burn patients, or others with severe skin damage.

Researchers are also working to identify new ways to grow skin cells in the lab. Epidermal stem cells are currently cultivated on a layer of cells from rodents, called feeder cells. These cell culture conditions have been proved safe, but it would be preferable to avoid using animal products when cultivating cells that will be transplanted into patients. So, researchers are searching for effective cell culture conditions that will not require the use of rodent cells.

Scientists are also working to treat genetic diseases affecting the skin. Since skin stem cells can be cultivated in laboratories, researchers can genetically modify the cells, for example by inserting a missing gene. The correctly modified cells can be selected, grown and multiplied in the lab, then transplanted back onto the patient. Epidermolysis Bullosa is one example of a genetic skin disease, where patients can benefit from this approach. Work is underway to test the technique.

More:
Skin stem cells: where do they live and what can they do? | Eurostemcell - Stem Cell Research | Uses of Stem Cells and Ethics | EuroStemCell

Skin Stem Cells Comments Off on Skin stem cells: where do they live and what can they do? | Eurostemcell – Stem Cell Research | Uses of Stem Cells and Ethics | EuroStemCell | May 16th, 2019

Our signature chemical peels help to reverse the visible effects of damage in two ways. First, they power away dull, dead cells to illuminate the skin and reduce the appearance of fine lines, wrinkles, age spots, clogged pores and blemishes. Then, they support collagen for firmer-looking skin over time. Ask your esthetician which IMAGE chemical peel will best target your skins individual needs.

I PEEL | WRINKLE LIFT

Ultra-resurfacing blend of glycolic acid combined with retinol to visibly reduce the appearance of fine lines and wrinkles.

Skin type indications: Aging, wrinkles, rough complexion, uneven skin tone, smokers skin, tired/dull skin, oily/acne

I PEEL | WRINKLE LIFT FORTE

This advanced treatment is formulated with additional glycolic acid and an innovative blend of firming and anti-aging properties, to visibly reduce the appearance of fine lines and wrinkles.

Skin type indications: Advanced aging, wrinkles, rough complexion, uneven skin tone, smokers skin, tired/dull skin, oily/acne

I PEEL | PERFECTION LIFT

This distinct blend of active exfoliants works synergistically to visibly reduce the appearance of fine lines, correct uneven skin tone, smooth rough texture and reduce acne blemishes.

Skin type indications: Aging, pigmentation, acne

I PEEL | PERFECTION LIFT FORTE

This concentrated blend of lactic acid, salicylic acid and resorcinol works synergistically to quickly and effectively reduce the appearance of advanced aging, pigmentation and acne. This extra strength treatment reveals a younger you in a single treatment.

Skin type indications: Advanced aging, pigmentation, acne

I PEEL | ACNE LIFT

Blend of AHAs and BHAs with protective agents to effectively treat all grades of acne.

Acne, oily, acne-prone, aging

I PEEL | BETA LIFT

This powerful non-blended salicylic acid treatment quickly and effectively targets and improves moderate/severe acne. Skin type indications: Acne, oily, aging

I PEEL | LIGHTENING LIFT

Lactic acid blended with kojic acid and a cocktail of brightening agents to reduce all forms of pigmentation.

Skin type indications: Pigmentation, aging, dry/dehydrated, uneven skin tone, age spots, redness-prone

I PEEL | LIGHTENING LIFT FORTE

This results-driven treatment combines the most innovative and effective botanical brighteners with echinacea, plant-derived stem cells and anti-aging peptides for youthful, illuminated skin.

Skin type indications: Advanced pigmentation, aging, dry/dehydrated, uneven skin tone, age spots, redness-prone

View post:
TREATMENTS - IMAGE NOW. Age later.

Skin Stem Cells Comments Off on TREATMENTS – IMAGE NOW. Age later. | May 12th, 2019

Stem cells explained: What are they, and how do they work?

What are stem cells and how do they work?

There are three types of stem cells. Each has potential for medical research and clinical applications based on its unique properties.

Peter Hoey, Special To The Chronicle

Stem cells are the building blocks of the human body. At the start of life, they divide over and over again to create a full person from an embryo. As we age, they replenish cells in our blood, bone, skin and organs. Stem cells could be powerful tools in treating injury and illness.

Embryonic Stem Cells

The first cells to form after a sperm fertilizes an egg.

Blank slate cells: can become every other kind of cell in the body.

Can divide and multiply endlessly.

Controversial in medicine because embryos must be destroyed to obtain stem cells.

Adult Stem Cells

Mature stem cells that replenish blood, skin, gut and some other cells.

In some cases, can replace cells damaged by illness or injury.

Limited ability to become other types of cells.

Limited ability to divide and multiply.

Induced-pluripotent Stem Cells

Adult cells that are reprogrammed to look and act like embryonic stem cells.

Can be made from skin, blood and other adult cells.

From their embryonic-like state, can be further altered to become any other type of cell.

Good potential use in medicine, but still a new area of research.

Embryonic

What are they?

Embryonic stem cells are the starter cells of the human body. They are undifferentiated, which means they have not matured and specialized, and they are able to become any other kind of cell in the body.

In embryos, these cells multiply and differentiate to become organs, bones and muscles. In the laboratory, they can be multiplied to create stem cell lines for study or for therapy.

Scientists harvest embryonic stem cells from three- to five-day-old embryos donated by people who have gone through in-vitro fertilization. Scientists isolated the first human embryonic stem cells in 1998.

What makes them different from other stem cells?

These are the only stem cells that naturally are able to become any other cell type and to multiply endlessly. Under the right circumstances in a lab, they can be nudged to become specific cell types.

Why do these characteristics give these cells medical potential?

Because of their ability to differentiate and multiply, embryonic stem cells long were thought to be the most powerful, and thus have the most potential for treating injury and disease. If scientists are able to control how they differentiate and how often, embryonic stem cells could be used to replace any damaged part of the body from missing insulin-making cells in people with Type 1 diabetes to brain cells lost in Parkinsons disease or skin cells scarred by burns.

What are the limitations of these therapies?

Many people have ethical problems using human embryos for scientific study. Also, embryonic stem cells ability to replicate endlessly means they may develop mutations that can interfere with their growth or allow them to keep dividing to the point of causing harm. Finding the right medical applications for embryonic stem cells is challenging.

Adult

What are they?

Adult stem cells are so-named because they are more mature than embryonic stem cells, though they dont necessarily have to come from adults. Their maturity means that they are limited in their ability to differentiate. Pockets of adult stem cells are found in many of our organs and they replenish cells in the organs in which they reside. Types of adult stem cells include:

Hematopoietic

Found in bone marrow and umbilical cord blood, they become blood and immune cells. They are the only stem cells approved by the FDA for therapy, for treatment of certain blood cancers.

Mesenchymal

These cells are found throughout the body, including in bone marrow, fat tissue and organs. They turn into the connective tissue found throughout the body, though the specific cell they become is related to the organ in which theyre located. These stem cells may decrease inflammation.

Fetal

Stem cells from fetuses are more mature, and therefore less able to differentiate, than embryonic stem cells, but they may be more multipurpose than other adult stem cells. For example, neural stem cells from fetal brain tissue can become several kinds of neurons, but neural stem cells from the adult brain are rare and have very limited ability to differentiate.

What makes them different from other stem cells?

Adult stem cells are limited in their abilities. They can only become certain types of cells they are called multi-potent, instead of pluripotent, for that reason and there is a limit to how often they can divide.

Why do these characteristics give these cells medical potential?

Adult stem cells are less powerful than embryonic, but they are easier to use, since all humans have their own supply of these cells. They may be useful for reducing inflammation.

What are the limitations of these therapies?

Its unclear how useful these stem cells could be given their limited abilities. Though the idea of tapping into a persons own source of adult stem cells and using them for treatment is appealing, these cells cannot repair serious injuries or replace cells lost to disease, like neurons or insulin-producing cells.

Induced-pluripotent

What are they?

Induced-pluripotent stem (IPS) cells are adult cells often skin or blood cells that have been taken from an individual and reprogrammed in a lab to become like embryonic stem cells. Then, like embryonic stem cells, they can be developed into any other type of cell. So a skin cell could be turned into an embryonic-like cell and then further turned into a heart cell.

What makes them different from other stem cells?

Like embryonic stem cells, except they are manufactured in a lab. And since they come from an individual, they are an exact match to that individual. Scientists are still studying whether IPS cells could be used interchangeably with embryonic stem cells.

Why do these characteristics give these cells medical potential?

They could be used to replace cell types lost to disease or injury. In addition, IPS cells can be used to study human diseases in Petri dishes or in animals. Scientists can take skin cells from a person with a genetic mutation, convert those cells to IPS cells, then study those cells as a living model of how the mutation functions.

What are the limitations of these therapies?

Making IPS cells can be a time- and resource-consuming process. But mostly, IPS cells have the same limits as embryonic stem cells.

The rest is here:
Stem cells explained: What are they, and how do they work?

Skin Stem Cells Comments Off on Stem cells explained: What are they, and how do they work? | May 12th, 2019

New research from the University of Southern California has come to light that fasting as little as eight (8) days a year could deliver significant health benefits, especially when it comes to stem cells.

Believe it or not, fasting two to four days at a time (every six months) causes stem cells to awaken from their normal dormant state, and start regenerating.

Essentially, researchers discovered that fasting helped eliminate damaged and older cells, allowing new healthier cells to replace them completely, effectively renewing the immune system.

This is one of the first times any natural intervention has ever been shown to trigger this self-renewal.

Going a bit deeper In mice and humans, white blood cell counts were significantly lowered after long periods without food. These bodies are vital to the human immune system.

But, when their numbers decline to a critical point, pathways for hematopoietic stem cells were switched on. These cells manage the immune system and generate new blood.

When you starve, the system tries to save energy, and one of the things it can do to save energy is to recycle a lot of the immune cells that are not needed, especially those that may be damaged, Valter Longo of the USC Davis School of Gerontology, said.

Fasting for an extended period of time (up to 48 to 96 hours) changes the human body to consume fat reserves, glucose (sugar), and ketones. Unhealthy white blood cells are also broken down, so that in part, their components can be reused for new, thriving cells.

This is considered to be a cell recycling of sorts.

After a period of fasting, the bodys immune system will generate new blood cells when nutrients begin flowing back into the body.

The main point of interest in this study at USC, they were committed to knowing what drives body systems to rebuild the cells.

To go further into the science a bit

The study found that Protein kinase A, an enzyme known to inhibit cell regeneration, was reduced in the systems of people who are fasting. Concentrations of a growth-factor hormone called IGF-1 were also lowered in those who have not eaten in days.

Important note: you will want to be careful if you decide to fast on only water for extended periods of time. To protect yourself, fasting for two to four days at a time should be done under medical supervision.

Another approach to fasting which has produced beneficial results is time restricted eating or intermittent fasting. This form of fasting involves eating in an 8 hour window and not eating during the remaining 16 hours.

This could be during a span from noon to 8:00 pm or 9:00 am to 5:00 pm. This time period will be completely up to you, just as long as you limit your intake to a single eight hour duration.

Youre not limited to the amount of water, and intermittent fasting is growing in popularity but is still considered a secret in the stem cell community.

Fasting has been a widely used approach for generations going back to early civilization, but either as a survival, ritualistic, or weight loss tactic.

But now, we have the research to support that fasting is an incredibly powerful stem cell boosting secret that can return powerful results.

After this study (and others) surfaced, we became inspired to see what other natural alternative secrets are out there.

In the end, we were able to gather and expand on 7 Secrets PROVEN to Grow More Stem Cells.

Go here to see the original:
Grow Stem Cells with Fasting - The Healing Miracle

Skin Stem Cells Comments Off on Grow Stem Cells with Fasting – The Healing Miracle | May 12th, 2019

After 20 years in general and cosmetic medicine, in 2004 Dr Ralph Bright encountered his first experience with biological medicine. Dr. Bright performed a cosmetic fat transfer into a patients leg to improve the appearance of a split skin graft after having a cancerous growth removed.Typically, you will need to transfer the fat a few times to achieve the desired shape.

Thats when Dr. Bright read the work of Patricia Zuk which was published in 2001. He had come to understand, body fat actually contains numerous different cell lines that can help repair damage in your body.

Moving forward to 2008, Dr Bright was invited to teach veterinarians how to perform liposuction on dogs. This struck him as odd Why do dogs need liposuction?After signing a confidentiality waiver they showed Dr Bright a dog who looked perfectly healthy and commented, just 6 months ago this dog could not get off the ground because they were riddled with arthritis. The veterinarians were using the dogs own body fat to treat the dogs arthritis.

Later, in 2008 one of Dr Brights patients repetitively requestedI need this treatment for my arthritis, I need you to try it.After a lot of research, in 2009 Dr Bright agreed to treat her. This was Dr Brights very first patient for this process.In fact it was the very first patient to ever receive treatment for their osteoarthritis using their own body fat in Australia.

That patient responded phenomenally well, so we treated a series of 6 patients and published these results in the medical journals. These results prompted Dr. Bright to start the new medical company we got to know as Macquarie Stem Cells.

Fast forward 10 years, Macquarie Stem Cells now has multiple doctors, nurses, cell biologists, cell technicians, consultants with a team of allied health professionals. Our results are significantly better, with higher success rates for our patients receiving treatment.We also perform a significant amount of research using our own private funding, including an upcoming placebo controlled clinical trial.

Thats the thing about medicine and innovation, its scary and its risky but, at the end of the day someone has to get up and lead the way. This is our way of giving back to the community.

Visit link:
Macquarie Stem Cells Treatment - Sydney, Melbourne, Perth ...

Skin Stem Cells Comments Off on Macquarie Stem Cells Treatment – Sydney, Melbourne, Perth … | May 12th, 2019

Bone marrow failure occurs in individuals who produce an insufficient amount of red blood cells, white blood cells or platelets. Red blood cells transport oxygen to be distributed throughout the bodys tissue. White blood cells fight off infections that enter the body. Bone marrow also contains platelets, which trigger clotting, and thus help stop the blood flow when a wound occurs. [1]

Bone marrow failure is associated with three types of diseases, Fanconi anemia (FA), dyskeratosis congenita, and aplastic anemia. Fanconi anemia is an inherited blood disorder due to abnormal breakages in DNA genes. It is linked to hyperpigmentation, which is the darkening of an area of skin or nails caused by increased melanin. According to Histopathology, However, in about 30% of FA patients no physical abnormalities are found.[2] Dyskeratosis congenita often affects multiple parts of the body. Individuals with this disorder usually show changes in skin pigmentations, unusual fingernail growth, and mucosa leukoplakia; the inner part of the mouth is encased with white patches that may never resolve.[2] Aplastic anemia happens when bone marrow doesnt produce enough new blood cells throughout the body. Aplastic anemia is an acquired autoimmune disease, which occurs when the immune system mistakenly attacks and destroys healthy body tissue.[3]

Bone marrow failure in both children and adults can be either inherited or acquired. Inherited bone marrow failure is often the cause in young children, while older children and adults may acquire the disease later in life.[4] A maturation defect in genes is a common cause of inherited bone marrow failure.[5] The most common cause of acquired bone marrow failure is aplastic anemia.[5] Working with chemicals such as benzene could be a factor in causing the illness. Other factors include radiation or chemotherapy treatments, and immune system problems.

The two most common signs and symptoms of bone marrow failure are bleeding and bruising. Blood may be seen throughout the gums, nose or the skin, and tend to last longer than normal. Children have a bigger chance of seeing blood in their urine or stools, which results in digestive problems with an unpleasant scent. Individuals with this condition may also encounter tooth loss or tooth decay. Chronic fatigue, shortness of breath, and recurrent colds can also be symptoms of bone marrow failure.[6]

The type of treatment depends on the severity of the patients bone marrow failure disease. Blood transfusion is one treatment. Blood is collected from volunteer donors who agree to let doctors draw blood stem cells from their blood or bone marrow for transplantation.[7] Blood that is taken straight from collected blood stem cells is known as peripheral blood stem cell donation. A peripheral stem cell donor must have the same blood type as the patient receiving the blood cells. Once the stem cells are in the patients body through an IV, the cells mature and become blood cells. Before donation, a drug is injected into the donor, which increases the number of stem cells into their body. Feeling cold and lightheaded, having numbness around the mouth and cramping in the hands are common symptoms during the donation process. After the donation, the amount of time for recovery varies for every donor, But most stem cell donors are able to return to their usual activities within a few days to a week after donation.[7]

Read more:
Bone marrow failure - Wikipedia

Bone Marrow Stem Cells Comments Off on Bone marrow failure – Wikipedia | May 12th, 2019